Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney d...

Lead sponsor: Revelation Biosciences, Inc•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Revelation Biosciences, Inc

Design: Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose Study in Patients with Stage 3-4 CKD. This study is planned as a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease. This study will enroll up to 40 subjects in up to 5 cohorts. Each cohort will consist of 8 unique subjects, 6 assigned to Gemini and 2 assigned to placebo. All subjects will provide written informed consent and be screened for eligibility before enrollment. All eligibility criteria must be met prior to dosing. On Day 1, each study subject will receive a single IV dose (each total dose volume = 20 mL) via syringe pump for at least 10 minutes but not longer than 15 minutes and as per the institution's standard method. Time 0 starts once the entire dose is administered and the line has been flushed to ensure any residual drug is delivered. A Safety Review Committee (SRC) will assess safety and tolerability including AEs, after at least 6 subjects in each cohort have completed Day 8 to determine the subsequent cohort dose. If a grade 3 or higher adverse event is not experienced, as determined by the SRC, or the criteria for stopping dosing has not been met at a given cohort dose level, dose escalation will proceed to the next cohort and dose level. Dosing will continue until any cohort experiences a dose limiting toxicity (DLT), defined as a dose that causes any grade 3 or higher adverse event, or stopping criteria is met or the highest dose as determined in the Phase 1 study has been tolerated. If a dose is stopped due to a DLT or stopping criteria, cohorts scheduled at a higher dose will not be utilized. The SRC will meet to review safety and tolerability data and may determine if a lower dose can be given. This dose will be documented in the minutes and a dose recommendation memo which will be provided to the clinical sites. Once the maximum tolerated dose is determined, the dose will be repeated (Cohort 4) for a total of 16 subjects dosed at the highest level tolerated. The repeated dose cohort will consist of 8 unique subjects, 6 assigned to Gemini and 2 assigned to placebo. If the maximum tolerated dose is reached within the first 2 cohorts, the dose will be repeated until a minimum of 32 subjects are enrolled. If the highest dose determined in the Phase 1 study is tolerated, optional higher dosing of may be administered as determined by the SRC, or the same dose will be repeated. All visits will be conducted as an outpatient or via telephone.

Related studies

RECRUITINGNA

DIALysis With EXpanded Solute Removal

NCT06660277 · Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), and more

RECRUITINGNA

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

NCT06314503 · Renal Insufficiency, Chronic, Kidney Failure, Chronic, and more

RECRUITINGPhase 1/2

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

NCT06863194 · Kidney Disease, Chronic, Renal Insufficiency, Chronic, and more

RECRUITINGNA

Effects of Exogenous Ketosis on Proteinuria and Renal Function

NCT06867471 · Renal Insufficiency, Chronic, Polycystic Kidney Diseases, and more

Active Not RecruitingNA

Potassium Supplementation in CKD

NCT03253172 · Renal Insufficiency, Chronic, Potassium Depletion, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 29, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment40

Start dateJan 2025

Last updatedOct 29, 2025

Condition

Renal Insufficiency, Chronic Chronic Kidney Disease stage3 Chronic Kidney Disease stage4

Locations shown

California Institute of Renal Research

Chula Vista, California

California Institute of Renal Research

La Mesa, California

Clinical Advance Center, PLLC

San Antonio, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions